Crosscheck

Your medical. Crosschecked.

Other

Infliximab and your FAA medical

Tumor necrosis factor (TNF) blocking agent, biologic infusion
Other names: Remicade, Inflectra, Renflexis, Avsola

FAA guidance

Acceptable with conditions.

Wait

2 weeks

ground trial when starting

Different waits apply in other cases.

Examiner

The examiner can issue when the document's criteria are met

FAA label

ACCEPTABLE

Source: FAA, Biologics, Biosimilars, and Non-Biologics. FAA date 26 August 2026. Checked by Crosscheck 11 November 2026

The FAA lists infliximab as an acceptable biologic when the underlying condition qualifies, with a two-week ground trial when starting and 24 hours of no-fly after each infusion.

Track your medications
More detail: infliximabThe rest of Crosscheck's reading, in plain wordsOpen

Wait

  • 24 hours no-fly after each dose
  • a forty-eight hour ground trial when changing from one biologic or biosimilar to another for the same indication

Changing from one biologic or biosimilar to another for the same indication requires a 48-hour ground trial.

  • 14 days after starting: ground observation
  • 24 hours after each dose: no flying
Show the FAA's words: infliximabThe official FAA wording: two passages, each with its document and dateOpen
FAA, Biologics, Biosimilars, and Non-Biologics · FAA date 26 August 2026
Initial observation: All require a 2-week no-fly/ground trial to verify no side effects.
ACCEPTABLE BIOLOGICS - MONOTHERAPY MEDICATION Permitted if the underlying condition qualifies; consult the condition pages for details.
Tumor Necrosis Factor (TNF) Blocking Agent: infliximab (Inflectra; Remicade; Renflexis), 24 hours
FAA, Biologics, Biosimilars, and Non-Biologics · FAA date 26 August 2026
Changing from one biologic/biosimilar to another for the same indication requires a forty-eight (48) hour ground trial to mitigate any aeromedical risk.
Sources and dates: infliximabOne FAA document, with the FAA's date and when Crosscheck checked itOpen

Questions pilots ask

Each answer is built from the FAA guidance on this page. Its sources and dates are in the page.

What does the FAA say about infliximab for pilots?

FAA guidance: Acceptable with conditions. The FAA lists infliximab as an acceptable biologic when the underlying condition qualifies, with a two-week ground trial when starting and 24 hours of no-fly after each infusion. Changing from one biologic or biosimilar to another for the same indication requires a 48-hour ground trial. Crosscheck does not predict the FAA's decision.

How long is the FAA's wait for infliximab?

2-week ground trial when starting; 24 hours no-fly after each dose; a forty-eight hour ground trial when changing from one biologic or biosimilar to another for the same indication.

What does the examiner do for infliximab?

The examiner can issue when the document's criteria are met. Crosscheck does not predict the FAA's decision.

Related pages

Medication guidance alone does not determine whether a pilot is medically qualified to fly. The underlying condition, dosage, side effects, medication combinations, and certification history may affect FAA eligibility.

For informational purposes only. Not legal or medical advice.